Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action.”
In addition to plazomicin, our research and development pipeline includes two programs that specifically target infections caused by Pseudomonas aeruginosa, which we refer to as our antipseudomonal programs. We are also pursuing small molecule research programs targeting other essential gram-negative enzymes.